Previous 10 | Next 10 |
ST. LOUIS, July 11, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter. The MAGiC catheter is a robotically navigated ...
Stereotaxis (NYSE:STXS) stock rose ~7% June 23 after B. Riley started coverage of the robotic system maker with a Buy rating and a $6 price target. The rating is in contrast to the SA Quant Rating of Strong Sell, which takes in to accounts factors such as Profitabilit...
F-star Therapeutics (FSTX) +71% on being acquired for $161M. Boxed (BOXD) +20%. Weber (WEBR) +17%. Flex LNG (FLNG) +13% secures 24 years of contract backlog for three LNG carriers. Stereotaxis (STXS) +11% rated buy at B Riley. Co-Diagnostics (CODX) +10% as Monekeypox ...
ST. LOUIS, June 06, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP) ...
The following slide deck was published by Stereotaxis, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Stereotaxis, Inc. 2022 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Stereotaxis (NYSEMKT: STXS) Q1 2022 Earnings Call May 10, 2022 , 10:00 a.m. ET Continue reading For further details see: Stereotaxis (STXS) Q1 2022 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q1 2022 Earnings Conference Call May 10, 2022, 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Market Adam Maeder - Piper Sandler Alex Nowak - Craig...
Stereotaxis press release (NYSE:STXS): Q1 GAAP EPS of -$0.06 beats by $0.01. Revenue of $7M (-18.6% Y/Y) beats by $0.33M. For further details see: Stereotaxis GAAP EPS of -$0.06 beats by $0.01, revenue of $7M beats by $0.33M
ST. LOUIS, May 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022. “Stereotaxis demonstrated co...
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...